



## Incorporate Third Party Scoring in Accelerated Underwriting

---

Guizhou Hu, M.D., Ph.D.  
Vice President  
Chief Decision Analytics Officer



# Proprietary Notice



The material contained in this presentation has been prepared solely for informational purposes by Gen Re. The material is based on sources believed to be reliable and/or from proprietary data developed by Gen Re, but we do not represent as to its accuracy or its completeness. The content of this presentation is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.




Remove paramedical exams and laboratory fluid requirements from Full Underwriting (FU) yet preserve FU pricing (close to mortality neutral)

# Cost vs. Benefit



■ Cost ■ Benefit



# Three Key Questions



1. What is the **mortality compromise/slippage** of not having fluids and paramedical exam?
2. How much of **mortality recovery/compensated** by AU models?

Three mortality recovery mechanisms by AU models:

1. Identify features where the protective values of fluids and paramedical exam are lower.
  2. Use additional requirements (credit, Rx score) to differentiate mortality.
  3. Strengthens/tightens other underwriting requirements.
3. How much does **AU impact** applicants' movement between FU and AU products?

It is all about by how much.

# 1. Mortality Compromise/Slippage



- Mortality Compromise=Protective Values of Fluids/Exam
  - Hyperlipidemia, HBP, Kidney Function, Liver Function, undiagnosed diabetes, smoking
  - Sentinel effects
- How to Study This?
  - Retrospective company-specific study of FU business — *Simulate* AU results by ignoring the values of fluids and paramedical exam

AU							
FU	S Preferred	Preferred	STD	Rated	Decline	Sub Total	Mortality
S Preferred	40					40	60%
Preferred	3	29				32	80%
STD	1	2	11			14	100%
Rated	0	1	1	5		7	200%
Decline	0	1	0	0	6	7	500%
<b>Sub Total</b>	<b>44</b>	<b>33</b>	<b>12</b>	<b>5</b>	<b>6</b>	<b>100</b>	
<b>Mortality</b>	<b>62%</b>	<b>98%</b>	<b>108%</b>	<b>200%</b>	<b>500%</b>		
Aggregate mortality excluding decline							
	Mortality	Expected	Ratio				
AU	88%	80%	110%				
FU	83%	83%	100%				



## Challenges

- Unable to study sentinel effects
- Difficulty to determine exclusivity of UW decision attributable to Fluids/Exam
- No self-reported BP and Lipid in most FU applications

# Additional Studies on PV of Fluids/Exam



- Mortality Slippage on Standard and Better Class (in aggregate)
  - Industrywide mortality comparison FU vs. Simplified products
    - Confounded by SES/face amount
  - Industrywide lab/exam results study
    - Prevalence of impairments and associated debits
    - Over-estimate the exclusivity
  - Assuming a “break-even” point ( $PV=Cost$ )
    - For example, at age 45, male at face of 100K, 12% mortality saving equal to \$100 present value over 20 years



## 2. Mortality Recovery by AU Models



### Three Mechanisms

1

Identify features where the protective values of fluids and paramedical exam are lower.

2

Use additional requirements (credit, Rx score) to differentiate morality.

3

Strengthens/Tightens other underwriting criteria.

# 2.1 Mortality Recovery



Identify features while protective value of fluids and paramedical are low

- Predictive models that predict
  - Abnormal lab/BP
  - Smoking
  - FU decisions
- BE on applications to increase disclosure
- Limit AU to certain age and face amount band
- Access EMR, Medical Claims data

By how much and how to study it?

## 2.2 Mortality Recovery



Use *additional* requirements such as...

### LexisNexis Risk Classifier (LN\_RC) and Milliman Rx Risk Score

Mortality differentiation that goes *beyond* conventional medical FU (*independent* impact from FU)

How to quantify this?

## 2.3 Mortality Recovery



Tighten up other underwriting criteria to shift class distributions to higher risk class

Before

AU							
FU	S Preferred	Preferred	STD	Rated	Decline	Sub Total	Mortality
S Preferred	40					40	60%
Preferred	3	29				32	80%
STD	1	2	11			14	100%
Rated	0	1	1	5		7	200%
Decline	0	1	0	0	6	7	500%
<b>Sub Total</b>	<b>44</b>	<b>33</b>	<b>12</b>	<b>5</b>	<b>6</b>	<b>100</b>	
<b>Mortality</b>	<b>62%</b>	<b>98%</b>	<b>108%</b>	<b>200%</b>	<b>500%</b>		

Aggregate mortality excluding decline			
	Mortality	Expected	Ratio
AU	88%	80%	110%
FU	83%	83%	100%

After

AU							
FU	S Preferred	Preferred	STD	Rated	Decline	Sub Total	Mortality
S Preferred	30	5	5			40	60%
Preferred	1	22	6	3		32	80%
STD	1	2	11			14	100%
Rated	0	1	1	5		7	200%
Decline	0	1	0	0	6	7	500%
<b>Sub Total</b>	<b>32</b>	<b>31</b>	<b>23</b>	<b>8</b>	<b>6</b>	<b>100</b>	
<b>Mortality</b>	<b>62%</b>	<b>95%</b>	<b>90%</b>	<b>155%</b>	<b>500%</b>		

Aggregate mortality excluding decline			
	Mortality	Expected	Ratio
AU	88%	88%	100%
FU	83%	83%	100%

How does it impact taken-up rate?

# 3. AU Impacts on Anti-Selection



Distribution Channel/Marketing

---

Post-issue analytic (actual vs. expected)

---

Random hold out study



# Milliman Rx Score LexisNexis Risk Classifier

---

# The Milliman Rx Risk Score



Source: Milliman, 2017



Source: LexisNexis 2017





## Analysis in Research Population

	Milliman Study	LN Study
Population	13M	7M
Deaths	231K	126K

## Review Studies in Target Population


- Differ from research population?
- Independent of FU?
- Overlap/Correlation with FU?

---


## Compare two scores:

- Complement each other?

# Milliman's Risk Score in Research Population



# Milliman Risk Score and Mortality: Research vs. Target Population




Source: Milliman Study, 2016


# Milliman Score's Association with Full Underwriting



## Independence of FU



## Correlation with FU




Source: ? ? ? ? ?

# Risk Classifier<sup>®</sup> Score Predicts Mortality in Research Population



The highest risk score group has an SMR 4.9 times higher than that of the lowest risk score group.




Age 18-89

Expected deaths from the 2008 Primary VBT. SMR calculated as A/E divided by overall population A/E.


# Risk Classifier Predicts Mortality in Research/Target Population




## Research Population (N=6.5M, age 20-59)




## Subset of Research Population (SES=high, N=2M, age 20-59)



## Target Population\*



SES is defined by income, education, mortgage payment etc.




\* Source: LexisNexis study, 2016.


# Risk Classifier Score's Association with Full Underwriting




## Independence of FU




## Correlation with FU



## Mortality Differentiation by Duration Years



# Performance Variations Makes The Two Scores Complement Each Other



Scores percentile in risk ascending order vs. cumulative mortality





## Thank you

---

Guizhou Hu, M.D., Ph.D.  
VP, Chief Decision Analytics Officer  
guizhou.hu@genre.com  
203 352 3013  
Visit [genre.com](http://genre.com) for more info.